ENDRA Life Sciences Strengthens TAEUS® System Intellectual Property with Issuance of 24th U.S. Patent
March 08 2022 - 8:00AM
Business Wire
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the
United States Patent and Trademark Office has issued ENDRA a new
patent, U.S. Patent No. 11266314 (the ‘314 patent) titled “Method
and System for Determining a Material Type of an Object of
Interest.”
The ‘314 patent protects ENDRA's method and system for
determining a material type by utilizing TAEUS. The patent has
potential applications beyond liver measurements and even outside
the human body. In addition, the ‘314 patent serves as the parent
patent for current patent applications being prosecuted in both
China and Europe.
“This newly issued patent, our 24th in the U.S., supports our
strategy to protect ENDRA’s intellectual property, lead innovation
in the thermoacoustic sector and broaden the potential applications
for our proprietary TAEUS® technology for both clinical and
non-clinical applications," stated ENDRA's Chief Executive Officer
Francois Michelon. "We maintain a concerted effort to enhance the
defensive and offensive value of our patent portfolio in priority
markets. Our global intellectual property portfolio currently
stands at 89 assets, which we define as patents in preparation,
filed or issued.”
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
400,000 cart-based ultrasound systems in use globally today. TAEUS®
is initially focused on the measurement of fat in the liver as a
means to assess and monitor Non-Alcoholic Fatty Liver Disease
(NAFLD) and inflammation (NASH), chronic liver conditions that
affect over one billion people globally, and for which there are no
practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit
www.endrainc.com.
Forward-Looking Statements
All statements in this news release that are not based on
historical fact are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” "anticipate," “attempt,” "believe,"
"could," "estimate," "expect," “future,” "goal," "intend," "may,"
"plan," “possible,” “potential,” "seek," "should," "will," or other
comparable terms (including the negative of any of the foregoing),
although some forward-looking statements are expressed differently.
Examples of forward-looking statements for ENDRA include, among
others, estimates of the timing of future events and anticipated
results of our development efforts, including the timing for
receipt of required regulatory approvals and product launches,
expectations concerning ENDRA's business strategy, ENDRA’s ability
to find and maintain development partners, market acceptance of its
technology and the amount and nature of competition in its
industry, and its ability to protect its intellectual property.
Forward-looking statements involve inherent risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements as a result of various factors
including, among others, ENDRA’s ability to develop a commercially
feasible technology and its dependence on third parties to design
and manufacture its products; receipt of necessary regulatory
approvals; the impact of COVID-19 on ENDRA’s business plans;
ENDRA’s ability to find and maintain development partners, market
acceptance of ENDRA’s technology and the amount and nature of
competition in its industry; ENDRA’s ability to protect its
intellectual property; and the other risks and uncertainties
described in the Risk Factors and Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of the Company’s most recent Annual Report on Form 10-K and in
subsequently filed Quarterly Reports on Form 10-Q filed with the
Securities and Exchange Commission. You should not rely upon
forward-looking statements as predictions of future events. The
forward-looking statements made in this news release speak only as
of the date of issuance, and ENDRA assumes no obligation to update
any such forward-looking statements to reflect actual results or
changes in expectations, except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220303006050/en/
Company Contact: Irina Pestrikova Senior Director,
Finance investors@endrainc.com www.endrainc.com
Investor Relations Contact: Yvonne Briggs LHA Investor
Relations (310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Sep 2023 to Sep 2024